Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding a re-valuation within the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The material change reported is an increase in the notional allocation of Ordinary Share ADRs for specific individuals within the US Retirement Savings Plan. This adjustment occurred on January 13, 2006, following a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. The transaction was executed at a price of $51.60 per share and was notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- The filing reports a re-valuation of the US Retirement Savings Plan resulting in increased notional ADR allocations for nine named directors and executives.
- The transaction price for the ADRs was $51.60 per share.
- The notification was issued on January 17, 2006, for transactions occurring on January 13, 2006.
- This document does not contain financial statements or operational results for the company.